Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06561685
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-16
Brief Title:
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-label Multicenter Study of LY4050784 a Selective SMARCA2BRM Inhibitor in Advanced Solid Tumor Malignancies With SMARCA4BRG1 Alterations
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to find out whether the study drug LY4050784 is safe tolerable and effective in participants with locally advanced or metastatic solid tumors with a BRG1 Brahma-related gene 1 also known as SMARCA4 alteration who have previously received do not qualify for or are refusing standard of care treatments or there is no standard therapy available for the disease The study is conducted in two parts - phase Ia dose-escalation and phase Ib dose-optimization dose-expansion The study will last up to approximately 4 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None